Strategy, led by CEO Michael Saylor, is focusing on growing its digital credit instrument STRC to enhance Bitcoin acquisitions and increase BTC per share. The company is actively buying Bitcoin and repurchasing STRC shares to manage its balance sheet. Market confidence in STRC's growth has surged, with the probability of STRC hitting $100 by December 31 now at 91%, up from 80% a week ago. Investors should watch for further updates on Bitcoin purchase plans and STRC developments, as these will impact market sentiment and STRC's price trajectory.
The strategy to boost STRC growth is noted alongside a market where 32 of 50 major cryptocurrencies on Pluang rose today. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 02, 2026 03:52 WIB: AAVE rose 7.42% to Rp3.047.843 with a typical hold time of 105 days and Pluang order activity at 40% Sell / 60% Buy; COMP fell 3.45% to Rp429.188 with 24% Sell / 76% Buy; DOT decreased 3.32% to Rp21.329 with 31% Sell / 69% Buy.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
